Aurobino receives FDA nod for generic hypertension drug

Justine Varieur Cadet | | Cardiovascular Business | Structural Heart Disease
Aurobindo Pharma has received approval from the FDA for Fosinopril Sodium and hydrochlorothiazide (HCT) tablets, a generic equivalent of Bristol-Myers Squibb's ACE inhibitor Monopril HCT.

The Hyderabad, India-based company said its Fosinopril Sodium and HCT Tablets USP 10/12.5mg and 20/12.5mg is the generic equivalent to Monopril HCT tablets 10/12.5mg and 20/12.5mg of Bristol-Myers. Fosinopril Sodium and HCT Tablets are indicated for hypertension and fall under the cardiovascular system therapeutic segment. Aurobindo said it will launch the product shortly in the U.S.

Justine Varieur Cadet

Related Content

Treating younger patients with TAVR increases risk of death
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
New data put a spotlight on troubling TAVR trends
How robotic-assisted mitral valve repair compares to conventional surgery
Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data
Cardiology societies push Medicare to pay for tricuspid TEER

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup